Understand the source comparison
Run SS-LUP-332 Cycle: Protocol Comparison
Before finalising any phased peptide protocol, compare the staggered SS-LUP-332 approach against simultaneous multi-peptide stacks and single-agent protocols. The table below shows receptor kinetics, dosing frequency, and practical limitations for each approac
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before finalising any phased peptide protocol, compare the staggered SS-LUP-332 approach against simultaneous multi-peptide stacks and single-agent protocols. The table below shows receptor kinetics, dosing frequency, and practical limitations for each approach.
- SS-LUP-332 Phased
- GLP-1 agonism (semaglutide) + GHRH pulsatility (sermorelin) + GnRH suppression (leuprolide) staggered by 1–3 weeks
- Weekly semaglutide + daily sermorelin + single leuprolide depot
- Semaglutide 5 days, sermorelin <10 min, leuprolide depot 4–12 weeks
- Requires daily injections during sermorelin phase; leuprolide suppression persists beyond cycle end
- Best for research models investigating metabolic–endocrine interaction without simultaneous receptor saturation
- Simultaneous Stack
- All three peptides started same day
- Weekly semaglutide + daily sermorelin + depot leuprolide (single dose)
- Overlapping half-lives cause unpredictable feedback loop interactions
- GLP-1-mediated appetite suppression + testosterone suppression from leuprolide can compound energy deficit unpredictably
- High risk of receptor interference. Semaglutide's gastric slowing may alter sermorelin absorption kinetics
- Single-Agent GLP-1
- Semaglutide only (GLP-1 receptor agonism)
- Weekly subcutaneous injection
- 5-day half-life allows once-weekly dosing
- No growth hormone modulation; no testosterone suppression
- Cleanest single-mechanism approach for fat-loss and insulin sensitivity research. No confounding hormonal variables
- Sermorelin Monotherapy
- GHRH analog (growth hormone pulsatility only)
- Daily subcutaneous injection before bed
- <10 min plasma half-life; GH elevation lasts 2–3 hours
- Daily injection requirement; no appetite suppression or metabolic rate increase independent of GH
- Effective for GH secretion studies but lacks the satiety and insulin-sensitising effects of GLP-1 agonism